Challenges in the treatment of young people with type 2 diabetes
- PMID: 36738752
- DOI: 10.1016/S2213-8587(23)00030-X
Challenges in the treatment of young people with type 2 diabetes
Conflict of interest statement
SM has received honoraria for lectures from NovoNordisk and AstraZeneca; for participating in advisory boards from NovoNordisk, Sanofi, MSD, and Boehringer Ingelheim; and has received support for attending meetings from NovoNordisk and Sanofi.
Comment on
-
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical